ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CDMO Avid Bioservices Inc

8.25
0.05 (0.61%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Avid Bioservices Inc NASDAQ:CDMO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.05 0.61% 8.25 8.01 95.00 8.45 8.11 8.31 1,300,201 05:00:14

Peregrine Pharmaceuticals to Present at Biotech Showcase 2018

02/01/2018 1:05pm

GlobeNewswire Inc.


Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Avid Bioservices Charts.

Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company committed to improving patient lives by manufacturing and delivering high quality biologics, today announced that its president and chief executive officer, Roger J. Lias, Ph.D., will deliver a corporate presentation at the 10th Annual Biotech Showcase™, being held January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco.

Details of this presentation are as follows:

  • Biotech Showcase 2018Time/Date: 3:30 p.m. PT on Monday, January 8, 2018Location: Hilton San Francisco Union SquareRoom: Yosemite – B (Ballroom Level)

About Peregrine Pharmaceuticals, Inc.Peregrine Pharmaceuticals, Inc. is a company transitioning from an R&D focused business to a pure play contract development and manufacturing organization (CDMO).  Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com).

Peregrine is pursuing the licensing or sale of its proprietary R&D assets, including its lead immunotherapy candidate, bavituximab, which is currently being evaluated in clinical trials in combination with immune stimulating therapies for the treatment of various cancers.  For more information, please visit www.peregrineinc.com.

About Avid Bioservices, Inc. Avid Bioservices, a wholly owned subsidiary of Peregrine Pharmaceuticals, provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.  With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support.  The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization.  For more information about Avid, please visit www.avidbio.com.

Contacts:
Stephanie Diaz (Investors)	
Vida Strategic Partners	
415-675-7401		
sdiaz@vidasp.com		

Tim Brons (Media)	
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com

1 Year Avid Bioservices Chart

1 Year Avid Bioservices Chart

1 Month Avid Bioservices Chart

1 Month Avid Bioservices Chart

Your Recent History

Delayed Upgrade Clock